News

Portfolio Companies
in the News

Miach Orthopaedics Names New CFO, Company Director

September 27, 2021

Neuros Medical Announces Completion of Enrollment in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain

September 15, 2021

4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights

August 12, 2021

Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

August 12, 2021

LQT Therapeutics Announces Closing of US$19M Series A Financing

August 9, 2021

Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study

July 28, 2021

Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection

June 29, 2021

Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices

June 29, 2021

Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System

June 29, 2021

category

medtech

status

Current

headquarters

Plymouth, Minnesota

website

HistoSonics

HistoSonics has developed a system to destroy tumors completely non-invasively. Treatment is achieved using histotripsy, a novel form of energy that is safe, extremely precise, and able to be personalized for each patient. The initial indication is for treatment of liver tumors and the system is being studied in several other types of tumors.